Addiction Therapy Company Secures Major UK Endorsement
Source: Streetwise Reports  (2/7/23)
Pharmaceutical powerhouse Awakn has been awarded Innovative Licensing and Access Pathway (ILAP) access to UK markets. This classification, equivalent to FDA Breakthrough Therapy designation in the U.S., allows the company to expedite development growth in the region. More >

Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment
Source: Streetwise Reports  (1/24/23)
Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company. More >

Exploring Why The Economist Named this Biotech 'One To watch' in 2023
Source: Streetwise Reports  (1/23/23)
As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023. More >

Biotech at Good Entry Point for Investors, Analyst Says
Source: Andrew Partheniou  (12/20/22)
The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report. More >

Why One Fund Owns 13% of This Small-Cap Pharma
Source: Streetwise Reports  (12/12/22)
Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease.
More >

Blockchain Co. Signs Agreement With Insurance Co.
Source: Streetwise Reports  (11/22/22)
Global Compliance Applications Corp. signs an agreement with a South African insurance company to get into that country’s expanding cannabis industry. More >

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment
Source: Streetwise Reports  (11/14/22)
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon. More >

Potential ROI With German Biopharma Co. Notable
Source: Dr. Elemer Piros  (10/27/22)
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report. More >

Companies Use Blockchain To Connect Hemp Growers, Consumers
Source: Streetwise Reports  (10/19/22)
Industrial hemp is legal in all 50 states, and companies are working to get CBD, insulation, textiles, and biofuel made from it to the masses. These three companies hope their partnership will help connect the growers and buyers. More >

Biopharma Target Price 10 Times Current
Source: Dr. Elemer Piros  (10/6/22)
Read to learn why ROTH Capital Partners gave Atai Life Sciences NV a Buy rating and a target price 10 times its current. More >

Opportunity for Investors Found in Psychedelics Space
Source: Patrick R. Trucchio  (9/27/22)
Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report. More >

Biotech Co.'s Target Six Times Current Price
Source: Francois Brisebois  (9/13/22)
One Phase 2 clinical trial showing LSD reduced symptoms of anxiety bodes well for other studies of LSD in this indication. In light of this, Oppenheimer & Co. gave this biotech company a target price that is over six times its current share price. More >

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet
Source: Streetwise Reports  (9/12/22)
One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run. More >

Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling
Source: Clive Maund  (9/7/22)
Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen. More >

Healthcare Co. Wants Share of $17.5B Addiction Treatment Industry
Source: Jason McCarthy  (7/14/22)
One healthcare co. is currently rated a Buy and is making a push for a share of the $17.5-billion addiction treatment industry after a recent study showed its psychedelic-assisted psychotherapy treatment showed a significant decrease in alcohol use, noted a Maxim Group equity research report. More >

Analyst Sees 'Attractive Long-Term Economics' for Healthcare Co.
Source: Andrew Partheniou  (7/13/22)
One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments. More >

Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression
  (6/27/22)
In this trial, slated to commence next quarter, the biopharma will test the efficacy of its version of the psychedelic compound in this mental health indication, noted a ROTH Capital Partners report. More >

Cannabis Firm Posts Improved Q2 FY22 YOY
  (5/23/22)
Compared to the previous year, the company's overall operating results for the quarter are better, noted a Noble Capital Markets report. More >

Cannabis Firm Increases YOY Revenue By 352% in 2021
  (4/12/22)
The company is expected to outperform again in 2022 given its focus on strategic growth and acquisitions, noted a Noble Capital Markets report. More >

Cannabis Infused Beverage Company Stock in 'Very Good Spot' to Purchase
Source: Clive Maund  (4/4/22)
Technical analyst Clive Maund explains why he rates this company a strong speculative buy. More >

Mental Health Co. Hosts Phase II Trials for LSD, Psilocybin
Source: Streetwise Reports  (3/16/22)
This mental health company is pioneering a unique, new treatment for mental health issues such as depression and PTSD in which psychedelics are administered by medical professionals in specialized clinics. More >

Q1 Results of Cannabis Firm Down YoY
  (2/24/22)
Despite a dampened Q1 FY22 performance and an uncertain future, parts of a cannabis firm's story remain attractive, warranting a Market Perform rating, noted a Noble Capital Markets report. More >

Cannabis Cos. Expected to Post Better Revenues As of Q2/22
Source: Streetwise Reports  (2/18/22)
Whereas U.S. multistate cannabis operators are expected to do well in 2022, federal legalization of cannabis would give a jolt to companies of all sizes, noted a ROTH Capital Partners report. More >

Small-Cap Drug Co. Fights Clinicians' COVID Stress
Source: Streetwise Reports  (2/15/22)
In a recent interview with Streetwise Reports, Cybin Inc.'s General and IP Counsel Robert Mino explained the company's position at the forefront of mental health treatment via psychedelics. "This sector has the potential to improve the human condition on a massive scale." More >

Why These 2 Medical Experts Want a New Stroke Treatment
Source: Streetwise Reports  (2/14/22)
In the Feb. 10 episode of Streetwise Live!, Host Cyndi Edwards interviews two medical experts who discuss the need for a new stroke treatment, explain why today's stroke treatments are so limited and express their excitement around what Algernon Pharmaceuticals is testing with DMT.

More >